Self-driving vehicle development company Clearpath Robotics said today it picked up Intuitive Surgical‘s (NSDQ:ISRG) director of design & management Mike Hanuschik. Hanuschik led the design and product management for Intuitive Surgical’s flagship da Vinci surgical robot system, the market leading robotic surgery platform. The da Vinci is used in over 500,000 procedures annually, according to […]
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Histogen Inc. is declaring victory after a Southern California judge’s decision that its technique for growing human skin cells does not infringe a pair of patents covering SkinMedica’s NouriCel product line.
It’s the second time San Diego-based Histogen, which is primarily focused on regenerative medicine solutions for wound care, has touted a win from U.S. District Court Judge Janis Sammartino. The judge sided with Histogen on how the patents’ claims should be construed.
Histogenics Corp., fresh from a merger with fellow Bay State firm Prochon Biotech, has no plans for layoffs, contrary to a report in an Israeli journal.
The Globes new outlet, a business daily based in Rishon Le-Zion, Israel, reported yesterday that Histogenics "will make substantial cuts" to its R&D unit in Ness Ziona.
Histogen Inc. finally closed its Series A venture round.
The opened the round in May of 2008, but fundraising stalled in early 2009 when Carlsbad, Calif.-based SkinMedica Inc. sued the company for alleged patent infringement. Litigation related to the case is still ongoing.
The round’s investors included Secure Medical, Leonard Lavin, Lordship Ventures and Angus Mitchell.